Search

everythinglearnresearchcommunity

for

Search:↓

Pediatric patients with dystrophic epidermolysis bullosa face more hospital admissions, procedures, and complications than others.

I cannot summarize the document because it cannot be parsed.

The document's conclusion cannot be provided because the document is not available to parse.

A new DSG4 gene mutation causes hair defects in a young girl.

A new genetic disorder caused by an ODC1 mutation can be treated with DFMO.

The study found two new mutations in a Chinese patient with severe biotinidase deficiency.

People with Birt-Hogg-Dubé syndrome often have lung problems and delayed diagnosis, and better recognition of CT scan signs could improve diagnosis and management.

Minoxidil treatment improves heart defects in a DiGeorge syndrome model.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.

2,5-DBH shows promise for improving drugs in cancer, brain disorders, and infections.

2-DG reduces seizures by enhancing brain inhibition through specific receptor activation.

The document's conclusion cannot be provided because the content is not available to parse.

The scaffold with polydopamine and bioactive glass effectively promotes bone regeneration.

The Blood Glucose Management Service improved patient safety and outcomes in managing blood sugar in hospitalized patients.

Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.

DFMO treatment improves hair growth, muscle tone, and development in Bachmann-Bupp syndrome patients.

A model called PM-DBiGRU was developed for analyzing sentiments in drug reviews, and it performed better than other models, but struggled with complex sentences and situations requiring background knowledge.

Cladribine has known risks and potential new safety concerns, requiring careful monitoring.

Metabolite 7 is a strong inhibitor for Alzheimer's disease management.